Natixis Halozyme Therapeutics, Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Natixis holds 207 shares of HALO stock, worth $9,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares

207

Previous 194 6.7%

Holding current value

$9,840

Previous $10,000 10.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$51.3 - $64.42 $666 - $837	13 Added 6.7%	207 $11,000
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $1,212 - $1,510	36 Added 22.78%	194 $7,000
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $5,264 - $6,651	158 New	158 $5,000
Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $5.22 Million - $7.74 Million	130,247 Added 346.4%	167,847 $9.55 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $1.17 Million - $1.57 Million	-30,300 Reduced 44.62%	37,600 $1.49 Million
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $2.54 Million - $3.28 Million	67,900 New	67,900 $2.99 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $660,052 - $847,724	-20,646 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $954,281 - $1.22 Million	-29,990 Reduced 59.23%	20,646 $830,000
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $1.43 Million - $1.72 Million	37,051 Added 272.73%	50,636 $2.06 Million
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $893,320 - $1.18 Million	-23,000 Reduced 62.87%	13,585 $617,000
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $17.7 Million - $23.1 Million	-449,109 Reduced 92.47%	36,585 $1.53 Million
Q4 2020 Feb 12, 2021	BUY	$25.81 - $43.62 $12.5 Million - $21.2 Million	485,694 New	485,694 $20.7 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account